Precision Oncology 2.0™
Broadening the reach and impact of personalized medicine
Welcome to the era of Precision Oncology 2.0™
Aiming to deliver a fast, precise and lethal strike at cancer’s unique drivers
Before we launch a program against a new, high-value target, we always ask ourselves:
- Can selective target inhibition improve patients’ survival or quality of life beyond what’s possible with the current standard treatment?
- Can the target be dosed to achieve therapeutic effects without causing unmanageable and potentially toxic side effects?
- Can inhibiting the target offer benefits as part of combination therapy?
Why our work matters
We are developing drugs specifically designed to interact with validated cancer targets with greater selectivity and optimized pharmaceutical properties to improve their safety and efficacy.
Our world-class team is comprised of experts in cancer biology, medicinal chemistry, next-generation chemical proteomics, computational chemistry and molecular biophysics, machine learning, and drug development. Together, they have architected a new and innovative approach to target and drug discovery.